Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses
28 févr. 2022 09h00 HE
|
Celsion Corporation
Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years ...
Celsion Corporation Announces Stock Consolidation
28 févr. 2022 08h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate
31 janv. 2022 08h00 HE
|
Celsion Corporation
Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 ...
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
13 janv. 2022 17h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
10 janv. 2022 20h45 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...
Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update
15 nov. 2021 08h30 HE
|
Celsion CORP
Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE...
Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021
09 nov. 2021 09h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses
08 nov. 2021 09h00 HE
|
Celsion CORP
Application Approval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, Celsion has raised...
Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
08 nov. 2021 08h30 HE
|
Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress
15 oct. 2021 09h00 HE
|
Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation Monday, October 18 at 7:30 a.m. Eastern Time LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...